FDA
-
-
-
-
-
-
-
Axsome Therapeutics Initiates SUMMIT Phase 3 Trial of AXS-05 in Smoking Cessation
-
-
-
-
-
-
-
Axsome starts Phase 3 trial of solriamfetol in children with ADHD
-
-
-
-
-
-
-
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
-
-
-
-
-
-
-
Axsome Therapeutics to Participate in Upcoming Investor Conferences
-
-
-
-
-
-
-
Axsome AUVELITY wins FDA approval for Alzheimer's agitation treatment
-
-
-
-
-
-
-
Oppenheimer on Axsome Therapeutics (AXSM): balipodect acquisition bolsters late-stage pipeline
-
-
-
-
-
-
-
Axsome Therapeutics (AXSM) PT Raised to $215 at TD Cowen
-
334,842 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


